Maximum Tolerated Dose of CEP-37440 in Patients With Advanced or Metastatic Solid Tumors

Study Title
To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors
Teva Identifier
C37440/1108
ClinicalTrials.gov Identifier
NCT01922752
Study Status
Completed
Trial Condition(s)
Solid Tumors
Interventions
Drug: CEP-37440

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age group
Adult, Older Adult
Age Range
18 Years and older
Trial Duration
07/01/2013 - 12/01/2015
Phase
Phase 1

Study Type

Interventional